64,245 results on '"Non‐alcoholic Fatty Liver Disease"'
Search Results
2. Mitochondrial mechanism of florfenicol-induced nonalcoholic fatty liver disease in zebrafish using multi-omics technology
3. Non-alcoholic fatty liver disease is associated with structural covariance network reconfiguration in cognitively unimpaired adults with type 2 diabetes
4. Encapsulation of oleanolic acid into cyclodextrin metal-organic frameworks by co-crystallization: Preparation, structure characterization and its effect on a zebrafish larva NAFLD model
5. Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
6. Evaluating the Therapeutic Efficacy of Habb-e-Ghafis in Non-alcoholic Fatty Liver Disease, a Randomised, Single-Blind, Standard-Controlled Trial
7. Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
8. Qige Decoction attenuated non-alcoholic fatty liver disease through regulating SIRT6-PPARα-mediated fatty acid oxidation
9. FucoVital® inhibits fatty acid accumulation in liver cells in vitro and reduces triglycerides levels in patients with NAFLD
10. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
11. Role of USF1 in activating CYBA transcription and influencing NADPH-ROS-mediated oxidative stress and lipid accumulation in non-alcoholic fatty liver disease
12. Meteorin-like alleviates hepatic steatosis by regulating hepatic triglyceride secretion and fatty acid oxidation
13. Camellia seed oil exerts a more gradual influence on the progression of high-fat diet induced NAFLD mice compared to corn oil: Insights from gut microbiota and metabolomics
14. Oxymatrine reduces hepatic lipid synthesis in rat model of nonalcoholic steatohepatitis by regulating Sirt1/AMPK and LXR/Plin2/SREBP-1c pathways
15. Statins and non-alcoholic fatty liver disease: A concise review
16. Race/ethnicity-specific association between the American Heart Association’s new Life’s Essential 8 and stroke in US adults with nonalcoholic fatty liver disease: Evidence from NHANES 2005–2018
17. The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease
18. Metformin's modulation of gut microbiota and its implications for Non-Alcoholic Fatty Liver Disease(NAFLD): A network pharmacology and molecular dynamics study
19. Dietary inflammatory potential and metabolic (dysfunction)-associated steatotic liver disease and its complications: A comprehensive review
20. Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
21. Cassia mimosoides L. decoction improves non-alcoholic fatty liver disease by modulating the pregnane X receptor
22. Associations between brominated flame retardants exposure and non-alcoholic fatty liver disease: Mediation analysis in the NHANES
23. Oxymatrine relieves non-alcoholic fatty liver disease by promoting sirtuin 1/adenosine 5‘-monophosphate-activated protein kinase pathway and peroxisome proliferator activated receptor alpha-mediated hepatic fatty acid oxidation
24. Testosterone deficiency aggravates diet-induced non-alcoholic fatty liver disease by inducing hepatocyte ferroptosis via targeting BMAL1 in mice
25. Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025
26. Prolonged exposure to low-dose traffic-derived PM2.5 causes fatty liver disorder in mice
27. Cirrhose métabolique : une entité en plein essor
28. Diabetes-associated sleep fragmentation impairs liver and heart function via SIRT1-dependent epigenetic modulation of NADPH oxidase 4
29. Long-term outcomes following hepatectomy in patients with lean non-alcoholic fatty liver disease-associated hepatocellular carcinoma versus overweight and obese counterparts: A multicenter analysis
30. Human umbilical cord derived-mesenchymal stem cells alleviate lipid metabolism disturbances of hepatocytes via mitochondrial transport
31. Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD – a prospective interventional study
32. Air pollution exposure and prevalence of non-alcoholic fatty liver disease and related cirrhosis: A systematic review and meta-analysis
33. Trilobatin as a potential adjuvant therapy for NAFLD: Targeting AMPK-PPARα and Nrf2 antioxidant pathways
34. Unveiling dynamic alterations of lipid droplet polarity during NAFLD-triggered lipophagy utilizing a far-red fluorescent probe with large stokes shift
35. Deciphering the role of dietary modifications and gut dysbiosis in Non-Alcoholic Fatty Liver Disease
36. Glycoprotein nonmetastatic melanoma protein B is regulated by hepatic peroxisome proliferator-activated receptor γ in liver steatosis
37. The correlation between hepatic fat fraction on dual-energy CT and epicardial adipose tissue in patients with non-alcoholic fatty liver disease
38. Targeting regulation of lipid metabolism with polysaccharide of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease: A review
39. The trend in incidence of non-alcoholic fatty liver disease and its impact on cirrhosis and liver cancer: An analysis from Global Burden of Disease 2021
40. Metabolic restoration: Rhubarb polysaccharides as a shield against non-alcoholic fatty liver disease
41. IRF8 aggravates nonalcoholic fatty liver disease via BMAL1/PPARγ axis
42. Polarity-Sensitive fluorescent probes based on triphenylamine for fluorescence lifetime imaging of lipid droplets
43. A class of MicroRNAs as diagnostic biomarkers and therapeutic strategies in non-alcoholic fatty liver disease: A review
44. The relationship between nutrient intake, lifestyle, and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Results from the National Health and Nutrition Examination Surveys 2007–2018
45. Liver lipid metabolism, oxidative stress, and inflammation in glutamine-supplemented ob/ob mice
46. Cracking the code: lncRNA-miRNA-mRNA integrated network analysis unveiling lncRNAs as promising non-invasive NAFLD biomarkers toward precision diagnosis
47. Near-infrared fluorescence imaging tool with large Stokes shift for sensitively detecting carboxylesterase 2 and monitoring its expression in non-alcoholic fatty liver disease
48. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver
49. Copper oxide nanoparticles induce non-alcoholic fatty liver disease by disrupting bile acid homeostasis and perturbing the intestinal microbial homeostasis
50. Pedalitin could regulate lipid metabolism and attenuate inflammatory factors in a non-alcoholic fatty liver disease cell model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.